Fig. 3

AXL knockdown sensitized EGFR-mutated NSCLC cells to osimertinib in vitro. a Nonspecific siRNA control or AXL-specific siRNAs (#1 and #2) were introduced into PC-9, PC-9GXR, HCC4011, HCC827, and H3255 cells. After 24 h, the cells were incubated with osimertinib (100 nmol/L) or gefitinib (100 nmol/L) for 72 h and the cell growth was determined using MTT assays. The percentage of growth is shown relative to the growth of untreated control cells. b Quantitative determination of the inhibition of cell viability of high-AXL-expressing and low-AXL-expressing EGFR-mutant cells transfected with nonspecific siRNA control or AXL-specific siRNAs after treatment with osimertinib or gefitinib. Paired Student’s t tests were used for comparisons. c Nonspecific siRNA control or AXL-specific siRNAs were introduced into PC-9, PC-9GXR, and HCC4011 cells. After 24 h, the cells were incubated with osimertinib (100 nmol/L) for 1 h. The cells were lysed and the indicated proteins were detected by western blotting